Treat Health
AI-assisted online doctor service providing employer-sponsored access to licensed physicians in minutes.
Website: https://treat.health/en/
Cover Block
Open sources
| Field | Value |
|---|---|
| Company | Treat Health |
| Tagline | AI-assisted online doctor service providing employer-sponsored access to licensed physicians in minutes. |
| Headquarters | Helsinki, Finland [Tech Funding News, November 2026] |
| Founded | 2026 [tech.eu, November 2026] |
| Stage | Pre-Seed [Tech Funding News, November 2026] |
| Business Model | B2B2C |
| Industry | Healthtech [EU-Startups] |
| Technology | AI / Machine Learning [EU-Startups] |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Sami Marttinen, Antti Mauno, Onni Wahlberg, Viljami Kuosmanen [Pomegra, November 2026] [Viljami Kuosmanen - epilot GmbH |
| Funding Label | Pre-seed, total disclosed approximately $3,300,000 [Tech Funding News, November 2026] [Seedtable] |
Links
Open sources
- Website: https://treat.health/
- Careers: https://treat.health/en/careers/full-stack-engineer/
What an Investor Needs First
PUBLIC Treat Health is a Helsinki-based healthtech startup building an employer-sponsored, AI-assisted online doctor service, and it merits investor attention now because it has paired an experienced repeat founder with an early financing event and initial pilot uptake in a category where workflow design matters as much as model claims [Tech Funding News, November 2026] [tech.eu, November 2026] [Treat Health]. The company was founded in 2026, and reporting ties the original motivation to CEO Sami Marttinen’s experience watching a family member go through repeated doctor visits before receiving a diagnosis, a founding story that aligns with Treat’s stated focus on reducing friction in first-line care access [Jenni Kaiponen - Treat Health | LinkedIn] [Treat Health].
The product is straightforward in concept: patients describe symptoms by text or voice, the system gathers relevant context and checks coverage, and a licensed physician reviews the case before a digital consultation [Tech Funding News, November 2026] [tech.eu, November 2026]. That positioning matters because Treat is being sold as a supplement to existing occupational healthcare and private insurance, not as a full-stack replacement, and the company has also said it does not monetize downstream referrals, lab tests, or clinic visits, which, if borne out in practice, would be a meaningful contrast with utilization-linked care models [Pomegra, November 2026] [Tech Funding News, November 2026].
The founding bench is stronger than is typical at pre-seed. Marttinen previously co-founded and led Swappie, while Antti Mauno is identified in public sources as a physician and Onni Wahlberg is described as coming from an engineering leadership role in fintech; public materials also list Viljami Kuosmanen as a co-founder [TechCrunch, February 2022] [Antti Mauno - LinkedIn] [Pomegra, November 2026] [Viljami Kuosmanen - epilot GmbH | LinkedIn].
On financing, Treat announced a €3 million pre-seed round in November 2026, reported as about $3.3 million in some databases, led by byFounders and Illusian with Wave Ventures also participating [Tech Funding News, November 2026] [Seedtable] [The SaaS News, November 2026]. The commercial model is B2B2C through employers, and early traction claims remain preliminary but directionally relevant: Tech Funding News reported more than 20 pilot employers, first thousands of users, and one pilot employer with 1,300 employees [Tech Funding News, November 2026].
Over the next 12 to 18 months, the main points to watch are less about top-line volume and more about proof of repeatability: whether pilots convert into durable employer contracts, whether physician-led response times and care navigation hold up as usage scales, and whether Treat can show that its supplement-to-insurance positioning translates into a distinct budget line rather than a nice-to-have benefit [Tech Funding News, November 2026] [tech.eu, November 2026] [Treat Health]. At this stage, the company has a credible wedge and credible founders, but most of the operating evidence in public view still comes from the launch-period funding narrative rather than from independently verified longitudinal performance data [Tech Funding News, November 2026] [Morning Tick, November 2026].
Partially corroborated -- Relies on one independently reported funding event and corroborated founder background, but several traction and product-detail claims are supported by a single news report or company materials.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | B2B2C |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Pre-seed, total disclosed about $3.3M [Tech Funding News, November 2026] [Seedtable] |
Inside the Company
PUBLIC Treat Health presents as a very new Helsinki-based healthtech company, and the public record is still thin enough that chronology matters more than narrative flourish. The company website describes an online doctor service where a physician evaluates the case in minutes, with employer or insurance coverage potentially paying for the visit [Treat Health]. Crunchbase classifies Treat Health as a Finnish company in health care and artificial intelligence, with headquarters in Helsinki and a 2026 founding year [Crunchbase].
The public timeline starts in 2026, with Crunchbase listing the company as founded that year and the website already live with an English-language employer and patient-facing flow [Crunchbase] [Treat Health]. In November 2026, Crunchbase records a pre-seed financing round, which aligns with broader public database coverage of an early institutional raise [Crunchbase]. No legal entity detail, incorporation filing, or fuller corporate history was confirmed from the permitted sources used for this section, so the clearest read is that Treat moved from formation to external funding within its first year on the market [Crunchbase] [Treat Health].
Partially corroborated -- This section relies on Crunchbase and the company website, with company identity and HQ corroborated but milestone depth limited by the permitted source set.
Under the Hood
MIXED Treat Health is selling a fairly specific care workflow, not a general wellness layer. Public reporting and the company website describe an employer-sponsored online doctor service in which a patient starts by describing symptoms by text or voice, the system gathers follow-up information and checks what the user’s coverage includes, and a licensed physician reviews the case before the digital consultation begins [Treat Health] [Tech Funding News, November 2026] [tech.eu, November 2026]. The company and third-party coverage also say doctors can provide advice, treatment, prescription renewals, or sick-leave certificates where appropriate, which places the product squarely in first-contact triage and routine primary-care handling rather than specialist care replacement [Treat Health] [Tech Funding News, November 2026].
The product positioning is equally narrow, and that is probably the most important design choice visible from public evidence. Treat is presented as a workplace health benefit that sits alongside existing occupational healthcare and private insurance, with the stated aim of giving users a clear first step into care while routing them onward when needed [Treat Health] [Pomegra, November 2026] [EU-Startups]. Reporting adds one notable economic claim: Treat reportedly does not make money from downstream lab tests, clinic visits, or referrals, an arrangement the company frames as reducing incentives for unnecessary utilization, though that point appears to rest on a single reported description and should be treated cautiously [Tech Funding News, November 2026].
There is little hard public evidence yet on the underlying technical stack, clinical automation depth, or measured model performance. The visible facts support AI-assisted intake and physician-reviewed case preparation, but they do not establish autonomous diagnosis, proprietary foundation models, predictive monitoring, or deeper integration breadth with insurers and occupational health systems [tech.eu, November 2026] [Treat Health]. The one surfaced open role, Full-stack Engineer in Helsinki [PUBLIC], signals active product buildout but does not by itself justify stronger stack claims (inferred from job postings) [Treat Health].
Partially corroborated -- Product workflow is corroborated by the company website and November 2026 funding coverage, but several specific capability and incentive claims rely on single-source reporting or company language.
Market Research
PUBLIC
The market matters now because employers across Europe are still looking for faster, lower-friction entry points into care, while digital triage and telemedicine workflows have become easier to distribute as a benefit rather than a full insurance replacement [tech.eu, November 2026] [Tech Funding News, November 2026] [Treat Health].
The evidence base on market size is thin, so the cleaner way to frame Treat Health is through adjacent categories rather than a claimed standalone TAM. Public reporting describes Treat as an employer-sponsored online doctor service that sits alongside occupational healthcare and private insurance, with AI-assisted intake feeding into a licensed physician review [tech.eu, November 2026] [EU-Startups] [Treat Health]. That places it at the intersection of three existing spend pools: employer health benefits, virtual primary care, and care-navigation or triage software. None of the captured sources provide a third-party TAM, SAM, or SOM for Treat’s exact segment, so any size discussion beyond those adjacencies would be speculative.
A small public dataset still shows why employers may test this model early. Tech Funding News reported more than 20 pilot employers, mostly global businesses, plus the company’s first thousands of users, and cited one pilot employer with 1,300 employees [Tech Funding News, November 2026]. Those figures are not market size, but they do suggest a live demand signal from employers willing to trial a supplemental care-access layer before replacing incumbent health coverage.
| Market lens | Public evidence | What it suggests for Treat |
|---|---|---|
| Employer-sponsored care access | Treat is sold through employers and positioned alongside existing occupational healthcare and private insurance [tech.eu, November 2026] [Pomegra, November 2026] | Budget likely competes for benefits spend rather than core insurer premium dollars |
| Virtual primary care | Patients can describe symptoms by text or voice before a physician-led digital consultation [Tech Funding News, November 2026] [Treat Health] | Adoption depends on whether async intake shortens time to clinical resolution |
| Care navigation and triage | Treat states it aims to direct patients to the right next step and clarify coverage early in the journey [Treat Health] [tech.eu, November 2026] | The wedge may be reduced friction and fewer unnecessary appointments, if outcomes hold |
The practical takeaway is that Treat does not need to create a net-new budget category to find buyers. The nearer-term question is whether it can prove that a triage-first service improves employee access and employer cost control enough to earn a recurring slot inside benefits budgets.
Demand drivers in the public record are consistent, even if they are still mostly framed at a qualitative level. Treat’s own site emphasizes no-appointment access, rapid physician review, prescription renewals, sick-leave certificates where appropriate, and support in understanding what insurance or occupational care will cover [Treat Health]. Reporting from tech.eu and Tech Funding News adds the company’s argument that private healthcare incentives can favor additional visits and referrals, and that a doctor-informed intake layer could reduce unnecessary appointments by getting a patient to an informed first step faster [tech.eu, November 2026] [Tech Funding News, November 2026].
That logic fits a familiar employer-benefits pattern. Employers tend to adopt point solutions first where access friction is visible to employees and where incumbent systems are fragmented. In Treat’s case, the adjacent substitute is not only a traditional telemedicine visit, but also the status quo of employees trying to interpret symptoms, coverage, and next steps across occupational health, private insurance, and clinics on their own [Treat Health] [Pomegra, November 2026]. If the product works as described, its comparative advantage is less about replacing doctors and more about compressing the path into the right doctor or downstream service.
The substitute set is therefore broad. A buyer could keep relying on existing occupational healthcare providers, insurer-backed digital front doors, conventional telehealth apps, or employer EAP and navigation offerings, depending on local market structure. The public sources do not establish how Treat prices against those alternatives, nor do they show clinical or economic outcomes versus incumbents, which is the main gap in assessing how large the immediately addressable market really is [tech.eu, November 2026] [Tech Funding News, November 2026].
Regulation and macro conditions cut both ways. On the supportive side, Treat’s model keeps a licensed physician in the loop before digital consultation and presents itself as a supplement to existing healthcare systems rather than a replacement, which should lower buyer resistance in regulated care environments [EU-Startups] [Treat Health] [Pomegra, November 2026]. On the constraining side, healthcare delivery remains country-specific, especially around prescriptions, sick-leave documentation, reimbursement, and employer-linked care pathways. That means the commercial promise of a global employer channel does not automatically translate into simple multi-country rollout, even if initial pilots include international employers [Tech Funding News, November 2026].
The same macro factor that helps demand also raises the diligence bar. Employers continue to search for ways to control healthcare friction and absence-related productivity loss, but benefits budgets are scrutinized, and new care layers need evidence that they either improve access, reduce unnecessary utilization, or both. Public reporting shows early buyer curiosity. It does not yet show enough third-party outcome data to determine how much of the surrounding employer-health market is realistically serviceable in the next few years.
Partially corroborated -- Market structure is grounded in public company and publisher descriptions, but no independent third-party TAM data was captured for this exact segment, and several demand signals rely on single-source reporting from Tech Funding News.
Competition and Substitutes
MIXED Treat Health is not selling a full-stack insurance product or a replacement for occupational healthcare, it is inserting a faster, doctor-reviewed digital entry point into care, which places it against a mix of telehealth workflows, employer-benefit platforms, and healthcare-services operators rather than one clean peer set [Treat Health] [Pomegra, November 2026] [EU-Startups].
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Treat Health | Employer-sponsored, AI-assisted online doctor service where patients describe symptoms by text or voice and a licensed physician reviews the case before digital consultation | Pre-seed, $3.3M disclosed in November 2026 | Positioned as a supplement to existing occupational healthcare and private insurance, with a doctor in the loop before consultation | [Tech Funding News, November 2026] [EU-Startups] [Treat Health] |
| Access Healthcare | Healthcare services company named as a competitor in the research set | Not established in the provided public source set | Public materials provided here do not substantiate a like-for-like employer telehealth workflow against Treat Health | [Structured Facts] |
| Centivo | Healthcare company named as a competitor in the research set | Not established in the provided public source set | Public materials provided here do not substantiate a like-for-like Nordic employer digital-doctor workflow against Treat Health | [Structured Facts] |
| iMedX | Healthcare services company named as a competitor in the research set | Not established in the provided public source set | Public materials provided here do not substantiate a direct employer-sponsored clinical access model from the sources reviewed here | [Structured Facts] |
The table is useful mainly as a boundary marker. Treat Health's disclosed model is narrow and specific: employer distribution, AI-assisted intake, and physician review within minutes [Treat Health] [Tech Funding News, November 2026]. By contrast, the named competitors in the supplied record are not described in the cited material with enough precision to confirm a one-to-one overlap, which suggests the real competitive set is broader than the labels attached in early startup databases.
That broader map has three layers. First are incumbents: private insurers, occupational healthcare providers, and clinic networks that already sit in the employer benefit stack and therefore own budget, care pathways, and in many cases downstream referrals, even if Treat says it is meant to complement them rather than replace them [Pomegra, November 2026] [Treat Health]. Second are challengers: digital-first care products that promise faster triage and online physician access, the category where Treat is clearly trying to establish itself through chat-first intake and rapid review [EU-Startups] [Tech Funding News, November 2026]. Third are adjacent substitutes: any employee benefit that reduces friction to care, whether through insurance concierge layers, direct booking tools, or employer-paid virtual care access. In practice, Treat is competing for a place in the benefits bundle as much as it is competing consultation by consultation.
Treat's clearest edge today appears to be positioning rather than scale. The company is presenting itself as a neutral front door that does not make money from lab tests, clinic visits, or referrals, a claim that, if sustained, could resonate with employers wary of utilization incentives in private healthcare, though the evidence for that claim is still limited to early reporting [Tech Funding News, November 2026]. The second edge is team signal: Sami Marttinen's prior operating history at Swappie gives the company more commercial credibility than many pre-seed healthtech launches, while Antti Mauno's physician background strengthens the case that the workflow is being built with clinical practice in mind [TechCrunch, February 2022] [Antti Mauno - LinkedIn, retrieved 2026] [Pomegra, November 2026]. Both advantages are perishable. Positioning is easy for competitors to mimic in sales conversations, and founder pedigree matters less once buyers begin comparing integration depth, clinical outcomes, procurement friction, and renewal behavior.
The exposure is equally clear. Treat does not appear, from the public record here, to own the insurance relationship, the occupational health contract, or the downstream care network, which means larger incumbents can respond by bundling similar digital access into products they already control [Treat Health] [Pomegra, November 2026]. That makes the company's channel dependent on employers deciding an extra care-navigation layer is worth adding beside existing coverage. It also leaves Treat exposed to any competitor, named or otherwise, that can show tighter integration with benefits administration or stronger claims to reduced total healthcare spend. The most plausible "loser if Y" is Treat Health itself, if employers conclude that existing insurers or occupational-health vendors can replicate the intake-and-review experience without adding another vendor to the stack [Treat Health] [Tech Funding News, November 2026]. Over the next 18 months, the competitive outcome will likely turn less on feature novelty and more on whether Treat can convert pilots into embedded employer distribution before incumbents close the workflow gap.
Opportunity
PUBLIC The prize here is not a better telehealth front end, it is a shot at becoming the default first point of medical triage inside employer-sponsored care across Europe, a position that can concentrate patient demand, employer budgets, and clinically supervised workflow in one layer if execution holds [Treat Health] [tech.eu, November 2026] [Tech Funding News, November 2026].
The headline opportunity is fairly specific. Treat is selling into employers, not trying to win consumer acquisition one visit at a time, and it is positioning the product as a supplement to existing private insurance and occupational healthcare rather than a wholesale replacement [Pomegra, November 2026] [EU-Startups]. That matters because wedges that fit the current care stack usually face less buyer resistance than products that ask employers or insurers to rebuild benefits architecture from scratch. The public evidence also suggests the product is trying to solve a real coordination problem: patients submit symptoms by text or voice, the system gathers relevant information and checks coverage, and a physician reviews the case before consultation, with doctors then able to advise, treat, prescribe, or issue sick-leave certificates where appropriate [Tech Funding News, November 2026] [Treat Health]. If that workflow consistently routes employees to the right level of care faster, Treat could become the intake and navigation layer that sits upstream of a large share of routine private-care demand.
| Scenario | What happens | Catalyst | Why its plausible |
|---|---|---|---|
| Employer wedge to regional platform | Treat starts with pilots, then expands from a chat-doctor benefit into the standard first-stop layer for employer-sponsored care across large multinational workforces in Northern and Western Europe | One or more pilot employers converts to a broader rollout after demonstrating faster access and cleaner navigation into existing coverage [Tech Funding News, November 2026] | The company already says it has more than 20 pilot employers, mostly global businesses, and one cited pilot employer has 1,300 employees, which at minimum shows some enterprise willingness to test the model [Tech Funding News, November 2026] |
| Benefit-stack control point | Treat becomes the workflow that employers and insurers place in front of occupational health and private insurance usage, shaping where employees go next rather than owning every downstream service | A formal distribution or reimbursement relationship with an insurer, broker, or occupational health channel partner | The current positioning is explicitly additive to existing insurance and occupational healthcare, and the homepage states that an employer or insurance policy may cover the visit, which fits a partner-led expansion path better than a direct displacement story [Treat Health] [Pomegra, November 2026] |
| AI-assisted clinical operations engine | Treat turns its intake, history organization, and doctor briefing workflow into a scaled operating system for high-volume low-acuity consultations, improving doctor throughput and patient experience at the same time | Product evidence that the pre-consult workflow reduces handling time or unnecessary appointments without hurting outcomes | Public reporting already describes an AI-assisted intake that asks follow-up questions, organizes medical history, and briefs the physician before the consultation; that is exactly the part of the workflow where software can compound clinician time if it works in practice [tech.eu, November 2026] [Tech Funding News, November 2026] |
The compounding logic is visible even at this early stage, although still more concept than proof. Employer distribution creates a relatively efficient top-of-funnel because one sale can bring in hundreds or thousands of covered lives, and Treat has already reported first thousands of users through more than 20 pilot employers [Tech Funding News, November 2026]. If more cases flow through the system, Treat should accumulate better structured intake data, better physician briefing patterns, and better understanding of which cases can be resolved digitally versus routed onward. That can shorten time to care, make the product more useful to doctors, and give employers a stronger reason to keep Treat in the benefit stack. The companys stated model of not earning from lab tests, clinic visits, or referrals also matters here, because if buyers believe Treat is economically aligned toward appropriate routing rather than downstream utilization, renewal conversations may become easier [Tech Funding News, November 2026].
The size of the win is harder to pin down from public evidence because no market-sizing source is provided in the record, but there is still a bounded way to frame upside. If Treat became a scaled employer health-navigation platform across European benefits budgets, the relevant value would likely resemble software and care-navigation infrastructure rather than a narrow single-service clinic. A useful public anchor is founder Sami Marttinens prior company Swappie, which raised a $124 million Series C in 2022 as it expanded a category-defining operating model across Europe, showing that European investors will fund large platform ambitions when a local wedge proves durable [TechCrunch, February 2022]. That does not make Treat comparable on outcomes, but it does support the idea that a pan-European category leader can be financed into meaningful scale. Under the "Employer wedge to regional platform" scenario above, Treat could plausibly grow into a business valued in the high hundreds of millions of euros or more (scenario, not a forecast) if it owns the first interaction layer for a large employer base, demonstrates repeatable renewals, and expands across adjacent geographies and payer relationships. The stretch case rests less on telemedicine volume alone and more on becoming the decision point that determines where private-care demand goes next [Treat Health] [tech.eu, November 2026] [Tech Funding News, November 2026].
Partially corroborated -- This section relies on one well-cited funding announcement cluster and company materials for product and traction claims, with no independent public market-sizing source or disclosed operating metrics beyond pilots and early users.
Sources
Open sources
[Tech Funding News, November 2026] byFounders and Illusian back ex-Swappie CEO’s €3M AI healthtech Treat | https://techfundingnews.com/treat-raises-3m-pre-seed-ai-healthtech-helsinki/
[tech.eu, November 2026] Finnish healthtech Treat raises €3M to tackle inefficiencies in private healthcare | https://tech.eu/2026/11/17/finnish-healthtech-treat-raises-eur3m-to-tackle-inefficiencies-in-private-healthcare//
[Treat Health] Treat Health | Etävastaanotto ja chat-lääkäri minuuteissa | https://treat.health/en/
[Seedtable] Treat Health Raises 3.3M USD in Pre Seed Funding | Seedtable | https://seedtable.com/companies/treat-health/funding-rounds/pre-seed-2026-11
[The SaaS News, November 2026] Treat Raises €3M Pre-seed | https://www.thesaasnews.com/news/treat-raises-3m-pre-seed/
[Morning Tick, November 2026] Swappie Founder’s Treat Gets €3M For Doctor-By-Chat Care | https://morningtick.com/post/swappie-founders-treat-gets-eur3m-doctor-chat-care/
[Crunchbase] Treat Health - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/treat-health
[EU-Startups] Treat Health | EU-Startups | https://www.eu-startups.com/directory/treat-health
[TechCrunch, February 2022] iPhone refurbisher Swappie raises $124M Series C led by Verdane to scale in Europe | https://techcrunch.com/2022/02/15/iphone-refurbisher-swappie-raises-124m-series-c-led-by-verdane-to-scale-in-europe/
Articles about Treat Health
- Treat Health Lands Pilot Deals for Its AI-Powered Doctor Consultations — The Helsinki startup, led by ex-Swappie CEO Sami Marttinen, is selling its service as a supplement to existing occupational healthcare.